Search Beyond News…

Investors in Capricor Therapeutics face a September 28, 2026 deadline to apply as lead plaintiff in a securities fraud class action lawsuit filed by Kahn Swick & Foti

Executive summary: Kahn Swick & Foti announced that investors in Capricor Therapeutics must file lead plaintiff applications by September 28, 2026 in a securities fraud class action lawsuit. The lead plaintiff deadline determines who can direct the litigation and influences potential settlement terms; failing to meet it excludes investors from that influential role.

Who is involved: Capricor Therapeutics (Nasdaq: CAPR), its investors, Kahn Swick & Foti LLC, and Charles C. Foti Jr. as partner.

Likely next: Investors must submit applications before the deadline; the court will then appoint a lead plaintiff and the case will proceed through discovery and potential settlement or trial.

Kahn Swick & Foti, LLC, partnered with former Louisiana Attorney General Charles C. Foti Jr., notified Capricor Therapeutics shareholders of the September 28, 2026 cutoff to submit lead plaintiff applications in a putative class action. The notice follows the firm's pattern of issuing similar deadlines for multiple companies in late August 2026. Missing the deadline bars investors from assuming the lead plaintiff role, though they may still participate as class members.

Timeline

Analysis — what this means

Likely next events

Sectors affected

Regulatory implications

Historical parallels

Sources

Related cases

Browse the full archive →